{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:21:13Z","timestamp":1793319673422,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T00:00:00Z","timestamp":1703289600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006390","name":"University of Lausanne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006390","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) are reshaping the prognosis of many cancers, but often cause immune-related adverse events (irAEs). Among neurological irAEs, myositis is the most frequently reported. Our aim is to describe clinical and non-clinical characteristics, treatment and outcome of all irMyositis (skeletal limb-girdle and\/or ocular myositis) and irMyocarditis cases in our reference center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled all irMyositis\/irMyocarditis patients seen between 2018 and 2022. We reviewed demographics, clinical characteristics, biological, neurophysiological, imaging workup, treatment and outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 14 consecutive patients. The most frequent treatments were pembrolizumab (35%) or ipilimumab\u2013nivolumab combination (35%). Limb-girdle, ocular (non-fluctuating palpebral ptosis and\/or diplopia with or without ophthalmoparesis) and cardiac phenotypes were equally distributed, overlapping in 40% of cases. Ocular involvement was frequently misdiagnosed; review of brain MRIs disclosed initially missed signs of skeletal myositis in one patient and ocular myositis in 3. Seven patients had other co-existing irAEs. When performed, myography showed a myogenic pattern. CK was elevated in 8\/15 patients, troponin-T in 12\/12 and troponin-I in 7\/9 tested patients. ICI were discontinued in all cases, with further immunosuppressive treatment in nine patients. In most cases, neurological and cardiological outcome was good at last follow-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Myositis is a potentially severe irAE. Despite its heterogeneous presentation, some highly suggestive clinical symptoms, such as ocular involvement, or radiological signs should raise physicians\u2019 attention to avoid misdiagnosis. We thus recommend a multidisciplinary assessment (including complete neuromuscular evaluation) even in case of isolated myocarditis. Our series underlines the importance of an early diagnosis, since suspension of ICI and adequate treatment are usually associated with good functional outcome.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-023-12134-x","type":"journal-article","created":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T11:02:18Z","timestamp":1703329338000},"page":"1947-1958","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Immune checkpoint inhibitor-related myositis and myocarditis: diagnostic pitfalls and imaging contribution in a real-world, institutional case series"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6420-8124","authenticated-orcid":false,"given":"Alex","family":"Vicino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-9414","authenticated-orcid":false,"given":"Andreas F.","family":"Hottinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiya","family":"Latifyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Boughdad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-8504","authenticated-orcid":false,"given":"Fabio","family":"Becce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1429-1374","authenticated-orcid":false,"given":"John O.","family":"Prior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7788-1673","authenticated-orcid":false,"given":"Thierry","family":"Kuntzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3475-0101","authenticated-orcid":false,"given":"Jean-Philippe","family":"Brouland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-4561","authenticated-orcid":false,"given":"Vincent","family":"Dunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2095-2677","authenticated-orcid":false,"given":"Michel","family":"Obeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-3595","authenticated-orcid":false,"given":"Marie","family":"Th\u00e9audin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,23]]},"reference":[{"issue":"359","key":"12134_CR1","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"2018","author":"A Ribas","year":"1979","unstructured":"Ribas A, Wolchok JD (1979) Cancer immunotherapy using checkpoint blockade. Science 2018(359):1350\u20131355. https:\/\/doi.org\/10.1126\/science.aar4060","journal-title":"Science"},{"key":"12134_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1749-6632.2010.05919.x","volume":"1217","author":"BT Fife","year":"2011","unstructured":"Fife BT, Pauken KE (2011) The role of the PD-1 pathway in autoimmunity and peripheral tolerance. Ann N Y Acad Sci 1217:45\u201359. https:\/\/doi.org\/10.1111\/j.1749-6632.2010.05919.x","journal-title":"Ann N Y Acad Sci"},{"key":"12134_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711\u2013723. https:\/\/doi.org\/10.1056\/NEJMoa1003466","journal-title":"N Engl J Med"},{"key":"12134_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ (2018) Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol 62:29\u201339. https:\/\/doi.org\/10.1016\/j.intimp.2018.06.001","journal-title":"Int Immunopharmacol"},{"key":"12134_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158\u2013168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"12134_CR6","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","volume":"33","author":"J Haanen","year":"2022","unstructured":"Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C et al (2022) Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up \u2606. Ann Oncol 33:1217\u20131238. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.001","journal-title":"Ann Oncol"},{"key":"12134_CR7","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/S1470-2045(18)30828-3","volume":"20","author":"F Martins","year":"2019","unstructured":"Martins F, Sykiotis GP, Maillard M, Fraga M, Ribi C, Kuntzer T et al (2019) New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. Lancet Oncol 20:e54-64. https:\/\/doi.org\/10.1016\/S1470-2045(18)30828-3","journal-title":"Lancet Oncol"},{"key":"12134_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M et al (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"12134_CR9","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11912-019-0859-2","volume":"21","author":"PC Pan","year":"2019","unstructured":"Pan PC, Haggiagi A (2019) Neurologic immune-related adverse events associated with immune checkpoint inhibition. Curr Oncol Rep 21:108. https:\/\/doi.org\/10.1007\/s11912-019-0859-2","journal-title":"Curr Oncol Rep"},{"key":"12134_CR10","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Mu\u00f1iz-Castrillo S, Honnorat J et al (2021) Neurologic adverse events of immune checkpoint inhibitors. Neurology 96:754\u2013766. https:\/\/doi.org\/10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"12134_CR11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV et al (2020) Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"12134_CR12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","volume":"76","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, Werth VP, Pilkington C, de Visser M et al (2017) European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 76:1955\u20131964. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"12134_CR13","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","volume":"19","author":"JC van Swieten","year":"1988","unstructured":"van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J (1988) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19:604\u2013607. https:\/\/doi.org\/10.1161\/01.STR.19.5.604","journal-title":"Stroke"},{"key":"12134_CR14","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","volume":"140","author":"MP Bonaca","year":"2019","unstructured":"Bonaca MP, Olenchock BA, Salem J-E, Wiviott SD, Ederhy S, Cohen A et al (2019) Myocarditis in the setting of cancer therapeutics. Circulation 140:80\u201391. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034497","journal-title":"Circulation"},{"key":"12134_CR15","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","volume":"91","author":"M Touat","year":"2018","unstructured":"Touat M, Maisonobe T, Knauss S, Ben Hadj SO, Hervier B, Aur\u00e9 K et al (2018) Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. Neurology 91:e985\u2013e994. https:\/\/doi.org\/10.1212\/WNL.0000000000006124","journal-title":"Neurology"},{"key":"12134_CR16","doi-asserted-by":"publisher","first-page":"5753","DOI":"10.1093\/rheumatology\/keab249","volume":"60","author":"A Weill","year":"2021","unstructured":"Weill A, Delyon J, Descamps V, Deschamps L, Dinulescu M, Dupuy A et al (2021) Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study. Rheumatology 60:5753\u20135764. https:\/\/doi.org\/10.1093\/rheumatology\/keab249","journal-title":"Rheumatology"},{"key":"12134_CR17","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J et al (2017) Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation 136:2085\u20132087. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571","journal-title":"Circulation"},{"key":"12134_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem J-E, Sosman JA, Lebrun-Vignes B, Johnson DB (2018) Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. The Lancet 391:933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6","journal-title":"The Lancet"},{"key":"12134_CR19","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/cas.12961","volume":"107","author":"T Kimura","year":"2016","unstructured":"Kimura T, Fukushima S, Miyashita A, Aoi J, Jinnin M, Kosaka T et al (2016) Myasthenic crisis and polymyositis induced by one dose of nivolumab. Cancer Sci 107:1055\u20131058. https:\/\/doi.org\/10.1111\/cas.12961","journal-title":"Cancer Sci"},{"key":"12134_CR20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1093\/jjco\/hyv158","volume":"46","author":"T Shirai","year":"2016","unstructured":"Shirai T, Sano T, Kamijo F, Saito N, Miyake T, Kodaira M et al (2016) Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 46:86\u201388. https:\/\/doi.org\/10.1093\/jjco\/hyv158","journal-title":"Jpn J Clin Oncol"},{"key":"12134_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2019.02.023","volume":"399","author":"H So","year":"2019","unstructured":"So H, Ikeguchi R, Kobayashi M, Suzuki M, Shimizu Y, Kitagawa K (2019) PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis. J Neurol Sci 399:97\u2013100. https:\/\/doi.org\/10.1016\/j.jns.2019.02.023","journal-title":"J Neurol Sci"},{"key":"12134_CR22","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.1007\/s00415-020-10264-0","volume":"268","author":"I Lotan","year":"2021","unstructured":"Lotan I, Hellmann MA, Wilf-Yarkoni A, Steiner I (2021) Exacerbation of myasthenia gravis following corticosteroid treatment: what is the evidence? A systematic review. J Neurol 268:4573\u20134586. https:\/\/doi.org\/10.1007\/s00415-020-10264-0","journal-title":"J Neurol"},{"key":"12134_CR23","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/CJI.0000000000000167","volume":"40","author":"WK Wu","year":"2017","unstructured":"Wu WK, Broman KK, Brownie ER, Kauffmann RM (2017) Ipilimumab-induced Guillain-Barr\u00e9 syndrome presenting as dysautonomia: an unusual presentation of a rare complication of immunotherapy. J Immunother 40:196\u2013199. https:\/\/doi.org\/10.1097\/CJI.0000000000000167","journal-title":"J Immunother"},{"key":"12134_CR24","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.annonc.2020.05.005","volume":"31","author":"J Doms","year":"2020","unstructured":"Doms J, Prior JO, Peters S, Obeid M (2020) Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis. Ann Oncol 31:1273\u20131275. https:\/\/doi.org\/10.1016\/j.annonc.2020.05.005","journal-title":"Ann Oncol"},{"key":"12134_CR25","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A (2020) Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"12134_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa181","author":"S Shelly","year":"2020","unstructured":"Shelly S, Triplett JD, Pinto MV, Milone M, Diehn FE, Zekeridou A et al (2020) Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy. Brain Commun. https:\/\/doi.org\/10.1093\/braincomms\/fcaa181","journal-title":"Brain Commun"},{"key":"12134_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003594","volume":"9","author":"S Boughdad","year":"2021","unstructured":"Boughdad S, Latifyan S, Fenwick C, Bouchaab H, Suffiotti M, Moslehi JJ et al (2021) 68Ga-DOTATOC PET\/CT to detect immune checkpoint inhibitor-related myocarditis. J Immunother Cancer 9:e003594. https:\/\/doi.org\/10.1136\/jitc-2021-003594","journal-title":"J Immunother Cancer"},{"key":"12134_CR28","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ijcard.2015.05.073","volume":"194","author":"C Lapa","year":"2015","unstructured":"Lapa C, Reiter T, Li X, Werner RA, Samnick S, Jahns R et al (2015) Imaging of myocardial inflammation with somatostatin receptor based PET\/CT\u2014a comparison to cardiac MRI. Int J Cardiol 194:44\u201349. https:\/\/doi.org\/10.1016\/j.ijcard.2015.05.073","journal-title":"Int J Cardiol"},{"key":"12134_CR29","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41571-020-0400-4","volume":"17","author":"F Martins","year":"2020","unstructured":"Martins F, Obeid M (2020) Personalized treatment of immune-related adverse events\u2014balance is required. Nat Rev Clin Oncol 17:517\u2013517. https:\/\/doi.org\/10.1038\/s41571-020-0400-4","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12134-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-023-12134-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-023-12134-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T10:09:51Z","timestamp":1711534191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-023-12134-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,23]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["12134"],"URL":"https:\/\/doi.org\/10.1007\/s00415-023-12134-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,23]]},"assertion":[{"value":"3 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}